Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/3/2025 | $70.00 | Overweight | Morgan Stanley |
| 6/3/2025 | $79.00 | Equal-Weight → Overweight | Morgan Stanley |
| 6/3/2025 | $60.00 | Neutral → Buy | B. Riley Securities |
| 6/2/2025 | $51.00 | Neutral → Buy | BofA Securities |
| 5/20/2025 | $55.00 | Buy | Stifel |
| 3/13/2025 | $52.00 | Buy | Citigroup |
| 12/10/2024 | $60.00 | Buy | BTIG Research |
| 12/6/2024 | $55.00 | Market Perform | BMO Capital Markets |
Morgan Stanley resumed coverage of Kymera Therapeutics with a rating of Overweight and set a new price target of $70.00
Morgan Stanley upgraded Kymera Therapeutics from Equal-Weight to Overweight and set a new price target of $79.00
B. Riley Securities upgraded Kymera Therapeutics from Neutral to Buy and set a new price target of $60.00
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)